Skip to main content
Equibles

IFRX · InflaRx N.V.

Track IFRX — free

Use IFRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.22 -0.01 (-0.45%) At close · Sep 4
Rebalance outlook locked
Market Cap
$327.16M
Shares
147.37M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.22 Open$2.21 Day$2.16–2.38 52W close$0.83–2.74 Avg vol 30d951K Short int9.5M · 6.4% float · 9.5d Short vol31% DataJan 2020–Sep 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$177,252
Trailing 12 months
Net income (TTM)
−$49.30M
Trailing 12 months
Revenue growth YoY
+520.3%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.8%
Year over year · more shares
Price change (1Y)
+41.4%
Trailing year
Short interest
6.4%
Latest settlement · 9.5 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +47%
above
Price vs 50-day avg +10%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 73%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +21%
trailing
6-month return +144%
trailing
YTD return +120%
this year
Relative strength +129%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+72% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.42% of float · ▲ +1.5% MoM · 9.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
62 holders — near 3-yr high, broad support
Squeeze score 70
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 102%
annualized · 1-yr
Max drawdown −50%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+47% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
73% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+72% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.42% of float · ▲ +1.5% MoM · 9.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
62 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $2 · 73% Range high $3
vs 200-day avg +47% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IFRX
InflaRx N.V.
this stock
$327.16M +119.8% — — 6.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.42B +20.5% +46.2% 31.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.22B +7.2% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $64.25B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $60.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
62
% held
64.2%
Net QoQ
+75.7M sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Rising
Shares short
9.5M
Days to cover
9.5d
Change
+141.7K sh
View
Short Volume
Short vol %
31%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
900
Value
$1.8K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
41.8%
Week of
Jul 27, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 6, 2026
This year
14
View

Performance

5D 20D 120D MTD YTD
IFRX -0.5% +20.7% +144.0% +4.2% +119.8%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -0.6% +21.1% +128.8% +3.8% +106.9%
Key facts CIK 1708688 CUSIP N44821101 13F (30d) 48 filings 48 filers Visit website Investor relations